Intratumoral G100, a TLR4 Agonist, Induces Anti-Tumor Immune Responses and Tumor Regression in Patients With Merkel Cell Carcinoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0469
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pilot Study of Intratumoral G100, Toll-Like Receptor-4 (TLR4) Agonist, Therapy in Patients With Merkel Cell Carcinoma (MCC).

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Intratumoral Treatment of One Tumor Lesion With LTX-315 Induces Complete Tumor Regression and Long-Term Specific Protective Immune Responses in a Metastatic Rodent Tumor Model

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice With Tumoral T Lymphoblasts

Journal of Oncology
Oncology
2019English

Caveolin-2 Deficiency Induces a Rapid Anti-Tumor Immune Response Prior to Regression of Implanted Murine Lung Carcinoma Tumors

Scientific Reports
Multidisciplinary
2019English

Human Tumor-Derived Genomic DNA Transduced Into a Recipient Cell Induces Tumor-Specific Immune Responses Ex Vivo

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2002English

Anti-Tumor Immune Responses Induced by Radiotherapy: A Review

Fukushima Journal of Medical Sciences
Medicine
2015English

Autologous Tumor Cell Vaccination Combined With Systemic CpG-B and IFN-α Promotes Immune Activation and Induces Clinical Responses in Patients With Metastatic Renal Cell Carcinoma: A Phase II Trial

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Correlation Between Tumor Regression and T Cell Responses in Melanoma Patients Vaccinated With a MAGE Antigen

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2004English

Intratumoral Injection of Ad-Isf35 (Chimeric CD154) Breaks Tolerance and Induces Lymphoma Tumor Regression

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy